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Abstract 
SIRT2 deacetylates specific acetyllysine residues in diverse proteins, and is 
implicated in a variety of cellular processes. SIRT2 inhibition thus has potentials to treat 
human diseases, such as cancers and neurodegenerative disorders. I have recently 
developed a series of -trifluoroacetyllysine-containing macrocyclic peptides, which 
inhibit the SIRT2 activity more potently than most other known inhibitors. Here I report 
the crystal structure of human SIRT2 in complex with a macrocyclic peptide inhibitor, 
S2iL5, at 2.5-Å resolution. The structure revealed that S2iL5 binds to the active site of 
SIRT2 through extensive interactions. A structural comparison of the SIRT2–S2iL5 
complex with SIRT2 in the free form and in complex with ADP-ribose revealed that 
S2iL5 induces an open-to-closed domain movement and an unexpected helix-to-coil 
transition in a SIRT2-specific region. My findings unveiled the potential of macrocyclic 
peptides to bind target proteins by inducing dynamic structural changes. 
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Introduction 
Sirtuins are a family of evolutionarily conserved, nicotinamide adenine 
dinucleotide (NAD+)-dependent deacetylases 1. NAD+ functions as a co-substrate during 
the deacetylation reaction, such that the carbonyl oxygen of the - acetylamide group 
first attacks the C1’ of the N-ribose in NAD+ to form an O-alkylamidate intermediate 
upon the release of a nicotinamide group, and following several reaction steps give the 
free -amino-K residue and 2’-O-acetyl-ADP-ribose  (Figure 1A). The seven 
mammalian sirtuins, SIRT1–SIRT7, have distinct substrate specificities and subcellular 
localizations, and are implicated in a variety of biological processes, such as gene 
silencing, cell-cycle regulation, metabolism, apoptosis, longevity and cancer (Table 1) 
2,3. SIRT2 is primarily localized in the cytoplasm and nucleus, and it deacetylates 
specific acetyllysine residues in diverse proteins. For instance, the SIRT2-catalyzed 
deacetylation of -tubulin 4,5 and histone H4 4,6 functions in the regulation of cell-cycle 
progression, and its deacetylation of receptor-interacting protein 1 (RIP1) is responsible 
for the modulation of RIP1–RIP3 complex formation, and thus regulates programmed 
necrosis 7. In addition, the siRNA-mediated down-regulation of SIRT2 induces 
apoptosis in HeLa cells, caused by p53 accumulation 8. Moreover, SIRT2 is associated 
with the aggregation of neural proteins such as -synuclein 9 and huntingtin 10, and thus 
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SIRT2 inhibition prevents neurodegeneration in Parkinson’s disease 9 and Huntington’s 
disease 10 models. Collectively, the specific inhibition of SIRT2 has tremendous 
potentials to treat various human diseases. 
High-throughput and in silico screening campaigns have identified more than a 
dozen distinct inhibitors against a family of sirtuins 11-13, including SRT1720 14, Ex-527 
15, Suramin 16, thieno[3,2-d]pyrimidine-6-carboxamide-based inhibitors 11-13, and 
indole-based inhibitors 11-13. Crystallographic studies revealed that SRT1720 14 and 
Ex-527 15 occupy the peptide substrate- and NAD+-binding sites of sirtuins, respectively, 
and that Suramin 16 and the thieno[3,2-d]pyrimidine-6-carboxamides 11-13 occupy both 
the peptide substrate- and NAD+-binding sites. In addition, several mechanism-based 
peptidic inhibitors have also been developed 17. These inhibitors have an inert or poorly 
reactive moiety, such as -trifluoroacetylamide on lysine (KTfa) 18, which probably 
occupies the -acetylamide binding site of sirtuins (Figure 1B). However, most of these 
inhibitors exhibit modest potency and isoform-selectivity. Recently, I constructed a 
library of KTfa-containing macrocyclic peptides and screened for active species that 
strongly bind SIRT2 19, by means of the RaPID (random nonstandard peptide integrated 
discovery) system20,21. The discovered macrocyclic peptides are able to bind SIRT2 with 
dissociation constants (KDs) in the low nanomolar range, and they inhibit the 
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deacetylase activity with a similar range of IC50 values. Macrocyclic peptides usually 
show increased protease-resistance and potentially better cell permeability than linear 
peptides, and thus can serve as a preferred scaffold for drug development, as 
exemplified by the immunosuppressive cyclic peptide cyclosporin A 22. Although the 
RaPID system is a suitable technology to discover such potent macrocyclic peptides, 
including the aforementioned anti-SIRT2 inhibitors, it remains unclear how these 
macrocyclic peptides strongly bind SIRT2 and exhibit their inhibitory activities. 
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Figure 1 Reaction mechanism of sirtuins
(Quoted from Morimoto et al. 2012)
(A) Deacetylation mechanism of Sirtuin with peptides with ε-acetylamide on lysine.
ε-amino-K residue and 2’ -O-acetyl-ADP-ribose is produced.
(B) The inhibition mechanism of sirtuin by peptides with ε-trifluoroacetylamide on lysine.
ε-trifluoroacetylamide is supposed to occupy the ε-acetylamide binding site, resulting
in inhibiton of sirutin reaction.
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 Table 1. Function of human Sirtuin families 
Sirtuin Localization Activity Targets Key functions 
SIRT1 Nucleus and 
cytosol 
Deacetylase PGC-1α, 
FOXOs, 
NFκB, p53 
Metabolism, 
Inflammation 
SIRT2 Nucleus and 
Cytoplasm 
Deacetylase H4, 
α-tubulin, 
RIP1, p53 
Cell cycle, 
Necrosis,  
Myelination 
SIRT3 Mitochondria Deacetylase AceCS2, 
PGC-1a 
Fatty acid oxidation, 
Antioxidant defences 
SIRT4 Mitochondria ADP-ribosyltransferase GDH Insulin secretion, 
Suppression of fatty 
acid oxidation 
SIRT5 Mitochondria Deacetylase 
Demalonylase 
Desuccinylase 
Unknown Urea cycle 
SIRT6 Nucleus Deacetylase 
ADP-ribosyltransferase 
DNA 
polymerase β 
Genome stability, 
Metabolism 
SIRT7 Nucleolus Deacetylase RNA 
polymerase I 
Ribosomal DNA 
transcription 
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Experimental Procedures 
Chemical synthesis of macrocyclic peptides 
The S2iL5 peptide and its mutants were synthesized with amidated C-termini 
by standard Fmoc-based solid phase peptide synthesis. NovaPEG Rink Amide resin 
(Novabiochem) was used as the solid support. For the cyclized peptides, after 
elongation of the peptide chain, the resulting N-terminal -amino group was 
chloroacetylated by an incubation with a solution of 0.2 M chloroacetyl 
N-hydroxysuccinimide ester in DMF, with rotation for 40 min at room temperature. For 
the linear peptides, the N-terminal amino group was acetylated by an incubation with a 
solution of 0.5 M acetic anhydride and 0.25 M N,N-diisopropylethylamine in DMF, for 
40 min at room temperature. After washing the resin with DMF (2 ml, 3 times) and 
DCM (2 ml, 6 times), the peptides were cleaved from the resin and deprotected by an 
incubation with a solution of trifluoroacetic acid (TFA)/1,2-ethanedithiol/triisopropyl 
silane/water (92.5 : 2.5 : 2.5 : 2.5), with rotation at room temperature for 3 h. The 
solutions were concentrated in vacuo, and the cleaved peptides were then precipitated 
with diethyl ether. For cyclization, the resulting peptide pellets were dissolved in 20 ml 
of water/DMSO (1:1), and triethylamine was added to the solution to bring its pH to 
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around ten. After an incubation at room temperature for 30 min to promote the 
cyclization, the peptide solution was acidified by TFA and purified by reverse-phase 
HPLC, using a gradient of eluent B (0.1% TFA in acetonitrile) in eluent A (0.1% TFA in 
water). The purified peptides were lyophilized and dissolved in DMSO. 
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Protein preparation 
The gene encoding human SIRT2 (residues 1–370) was amplified by PCR, and 
cloned between the NdeI and XhoI sites of the modified pET28a vector (Novagen). The 
protein was expressed at 20°C in Escherichia coli Rosetta 2 (DE3) (Novagen), and 
purified by Ni-NTA Superflow resin (QIAGEN). The eluted protein was incubated with 
trypsin (1:100, w/w) for 2.5 h at 4ºC, since limited trypsin proteolysis of SIRT2 was 
found to produce a stable 36 kDa fragment, which was determined to be SIRT2 
(residues 43–370) using MALDI-TOF MS (Figure 2). The protein was further purified 
by chromatography on Resource Q (GE Healthcare) and HiLoad Superdex 200 16/60 
(GE Healthcare) columns (Figures 3 and 4). The purified protein was concentrated 
using an Amicon Ultra 30K filter (GE Healthcare). The expression vectors for the 
SIRT2 mutants were generated by a PCR-based method, using the expression vector for 
full-length SIRT2 as a template, and the sequences were verified by DNA sequencing. 
The mutant proteins were expressed at 20°C in E. coli Rosetta 2 (DE3), and purified 
with Ni-NTA Superflow resin. 
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Figure 2 SDS-PAGE and MALDI-TOF MS after trypsin digestion of SIRT2
(A) SDS-PAGE of SIRT2 before and after trypsin digestion. M, marker; 1, expressed SIRT2 
with His-Tag; 2, SIRT2 after trypsin digestion. Three major components were found (①-③)
and performed MALDI-TOF MS.
(B) Results of MALDI-TOF MS after trypsin digestion. Molecular weight of ①-③ were
determined to be 36669.5, 39314.3, 41265.2, respectively. The main component ( = ① )
is supposed to be SIRT2 of residues 43-370.
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Figure 3 Purificaion of SIRT2 with Resource Q
(A) Purification of SIRT2 with Resource Q. The output is in black and the gradient of
0.5 M NaCl is in skyblue. Fractions with underline were collected for SDS-PAGE.
(B) SDS-PAGE of SIRT2 after Resource Q. M, marker; B12 to C3 are fractions of 
Resource Q. B11-B6 (indicated with double underline) were collected for further purification.
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Figure 4 Purificaion of SIRT2 with SPDX 200
(A) Purification of SIRT2 with SPDX 200. Fractions with underline were collected for
SDS-PAGE.
(B) SDS-PAGE of SIRT2 after SPDX 200. M, marker; I, input sample; D4 to E8 are fractions
of  SPDX 200. D3-E2 (indicated with double underline) were collected for crystalliztion.
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Crystallography 
Purified SIRT2 (residues 43–370) was crystallized at 4ºC by the sitting-drop 
vapor diffusion method. SIRT2 (10 mg ml–1) was mixed with S2iL5 at a 1:2 
(SIRT2:S2iL5) molar ratio in 20 mM Tris-HCl, pH 8.0, 150 mM NaCl and 1 mM DTT. 
Crystals were obtained by mixing 0.5 l of protein solution and 0.5 l of reservoir 
solution (100 mM MES-NaOH, pH 7.0, 100 mM Li2SO4, 100 mM NaCl and 8.5% PEG 
4,000) (Figure 5). X-ray diffraction data were collected at 100 K on the beamline 
BL32XU at SPring-8 (Hyogo, Japan) (Figure 6). The crystals were cryoprotected in 
reservoir solution supplemented with 30% ethylene glycol. X-ray diffraction data were 
processed using HKL2000 (HKL Research, Inc.). The structure was determined by 
molecular replacement with MOLREP 23, using the SIRT2 structure in the free form 
(PDB ID 1J8F) as a search model. The model was built manually using COOT 24 and 
refined using PHENIX 25. The final model contains four SIRT2–S2iL5 complexes 
(residues 55–98 and 104–356 for Mol A, residues 56–100 and 107–356 for Mol B, 
residues 57–99 and 106–356 for Mol C, and residues 57–98 and 106–356 for Mol D), 
four zinc ions, and four MES, four ethylene glycol and 507 water molecules. Molecular 
graphic images were prepared using CueMol (http://www.cuemol.org). 
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Figure 5 Crystals of SIRT2-S2iL5 complex
Needle crystals of 400 µm were obtained.
100 µm
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Figure 6 Diffraction pattern of SIRT2-S2iL5 complex
Obtained diffraciton pattern obtained at SPring-8 BL32XU. The diffraction around 2.5 A
is enlarged.
3.00Α
2.50Α
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Surface plasmon resonance analysis 
SPR measurements were performed at 10°C on a Biacore T200 instrument (GE 
Healthcare) equipped with a Ni-NTA sensor chip. Modified HBS-EP+ (10 mM 
HEPES-KOH, pH 7.4, 150 mM NaCl, 50 M EDTA, 0.05% Tween 20, 0.1% DMSO) 
was used as the running buffer for all experiments. To collect kinetics data, a series of 
five different concentrations of each peptide was injected for 1 min at a flow rate of 30 
l min–1. Dissociation of the peptide was allowed to continue for 1 min between 
injections and 5 min after the final injection. Buffer blank injections were performed 
before and after the sample injection for double referencing with a negative control 
surface without protein immobilization, to monitor the background binding. Binding 
sensorgrams were fitted with the Biacore evaluation software. 
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Results and Discussion 
Crystal structure of human SIRT2 in complex with S2iL5 
To gain structural insights into their inhibitory mechanisms, I performed 
crystallization screening of human SIRT2 in the presence of several macrocyclic 
peptides, and successfully determined the crystal structure of SIRT2 in complex with 
one of the inhibitor peptides, S2iL5, at 2.5-Å resolution (Table 2 and Figure 7). The 
structure revealed that SIRT2 consists of a large Rossmann-fold domain (residues 55–91, 
146–186 and 241–356) and a small zinc-binding domain (residues 92–145 and 
187–240) (Figure 7), as in the structure of SIRT2 in the free form 26 (Figure 8). The 
asymmetric unit contains four SIRT2–S2iL5 complexes (Mol A–Mol D), which are 
essentially identical (r.m.s. deviation values for C atoms are less than 0.70 Å) (Figure 
9). Thus, I will hereafter describe Mol A. 
 S2iL5 consists of 14-amino acid (aa) residues cyclized via a thioether bond 
(Figure 10), and exhibits remarkably high affinity and inhibitory activity against SIRT2 
(KD = 1.0 nM at 10ºC and IC50 = 13 nM at 37ºC) (Figures 11 and 12). The bound S2iL5 
is clearly defined in the FO – FC omit electron density map (Figure 13; the SIRT2 and 
S2iL5 residues are denoted by the three-letter and one-letter codes, respectively). S2iL5 
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adopts a unique cyclic structure, which is stabilized by multiple intramolecular 
hydrogen bonds. The side chain of R8 is flipped inside the cyclic scaffold, and its 
guanidine head is nearly in the center. This positioning of the guanidine head is 
supported by direct hydrogen bonds with the carbonyl groups of Y4 and V6 and 
water-mediated hydrogen bonds with the carbonyl groups of R9 and N11. This R8 
residue adjacent to the KTfa is highly conserved among the selected macrocyclic peptide 
inhibitors 19, suggesting that it plays a crucial role in maintaining their tertiary structural 
integrity. Moreover, hydrogen-bonding interactions are formed between T3 and V6 and 
between H2 and the carbonyl group around the thioether linkage. This structure allows 
the presentation of the KTfa7 side chain outside the cyclic scaffold, for binding to SIRT2. 
I refer to this unique peptide structure as a “power button icon”-like (PBI-like) 
macrocycle, due to the shape similarity (Figure 10). 
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Table 2. Data collection and refinement statistics 
 SIRT2–S2iL5 
Data collection  
Space group P212121 
Cell dimensions  
   a, b, c (Å) 91.18, 135.61, 148.83 
   , ,  () 90, 90, 90 
Resolution (Å) 50.0–2.52 (2.56–2.52)* 
Rsym 0.148 (0.410) 
I / I 14.8 (3.4) 
Completeness (%) 98.6 (96.6) 
Redundancy 5.2 (3.9) 
  
Refinement  
Resolution (Å) 46.6–2.52 (2.56–2.52) 
No. reflections 61,346 
Rwork / Rfree 0.216 / 0.263 
No. atoms  
   Protein 9,323 
   Ligand/ion 644 
   Water 507 
B-factors  
   Protein 36.1 
   Ligand/ion 24.5 
   Water 27.6 
R.m.s. deviations  
   Bond lengths (Å) 0.003 
   Bond angles () 0.605 
*Values in parentheses are for highest-resolution shell. 
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S2iL5 recognition by SIRT2 
 S2iL5 binds to the active-site groove between the small and large domains of 
SIRT2, with the KTfa7 side chain inserted into the catalytic tunnel formed by His187, 
Val233 and Phe235 (Figures 14 and 15A). This is the first crystal structure of sirtuin in 
complex with a KTfa-containing peptide, and it confirmed that the KTfa residue occupies 
the acetyllysine-binding site of sirtuin. The hydrocarbon chain of KTfa7 is sandwiched 
by the side chains of His187 and Phe235, with its N atom hydrogen bonded to the 
carbonyl group of Val233 (Figures 14 and 15A). The amide and carbonyl groups of 
KTfa7 hydrogen bond with the carbonyl group of Glu237 and the amide group of Gly236 
in the small domain, respectively. In addition, the amide and carbonyl groups of R8 
hydrogen bond with the carbonyl and amide groups of Gln267 in the large domain, 
respectively. Consequently, SIRT2 and S2iL5 (KTfa7 and R8) form an intermolecular  
sheet-like interaction (Figures 14 and 15A). His187, Val233 and Phe235 are highly 
conserved among the sirtuin family members (Figure 15B), and the acetyllysine 
residues of the substrate peptides are recognized in a similar manner in other 
sirtuin–substrate peptide complex structures 27-31. For instance, in the 
SIRT3–AceCS-KAc complex structure, the side chain of KAc642 is sandwiched by the 
side chains of His248 and Phe294, with its N atom hydrogen bonded to the carbonyl 
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group of Val292 (Jin et al., 2009) (Figure 15B). The amide and carbonyl groups of 
KAc642 hydrogen bond with the carbonyl group of Glu296 and the amide group of 
Gly295, respectively, and the amide and carbonyl groups of V643 hydrogen bond with 
the carbonyl and amide groups of Glu325, respectively. 
 In addition to these interactions commonly observed in sirtuins, S2iL5 forms a 
number of hydrophilic and hydrophobic interactions with SIRT2, with a buried surface 
area of 845 Å2 (42% of the total surface area of S2iL5), which is larger than that for the 
SIRT3–AceCS-KAc complex (582 Å2) (Figures 14 and 15A). The R9 side chain of 
S2iL5 forms salt bridges with Glu116 and Glu120, and a cation- interaction with 
Phe235. Y4, H5 and T10 of S2iL5 hydrogen bond with Ser271, Leu239 and Gln265, 
respectively. The side chains of Y4 and H5 in S2iL5 form van der Waals interactions 
with the side chain of Phe244, which in turn forms an edge-to-face interaction with 
Phe243. In addition, S2iL5 interacts with a SIRT2-specific insertion loop (residues 
289–304) in the large domain (Figures 14 and 15A). Y12 of S2iL5 hydrogen bonds with 
Asp294, and Y1 and Y12 form van der Waals interactions with the side chain Met299, 
and Phe296 and Met301, respectively. The insertion loop is unique to SIRT2 (Figure 16), 
thus partly explaining why S2iL5 binds SIRT2 (KD = 1.0 nM) more potently than SIRT3 
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(KD = 1.8 nM) (Figure 11A). Altogether, the present structure revealed that S2iL5 
adopts a PBI-like structure to achieve extensive interactions with SIRT2. 
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Figure 7 Crystal structure of SIRT2-S2iL5 complex
(A) Overall structures of SIRT2 in complex with S2iL5. The small and large domains are colored 
yellow-green and cyan, respectively. S2iL5 is shown as a stick model, in which the carbon atoms 
are yellow, oxygen atoms are red, nitrogen atoms are blue and the fluorine atom is gray. The bound 
zinc ion is shown as a gray sphere. The cofactor-binding loop (residues 92–104) and the 
SIRT2-specific insertion (residues 289–304) are colored green and magenta, respectively. 
The disordered region (residues 99–103) in the S2iL5 complex is indicated by green dots.
(B) Molecular surfaces of SIRT2 in the complex with S2iL5. The molecular surface of SIRT2 alone, 
in which S2iL5 is omitted from the complex, is also shown.
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Figure 8 Crystal structure of SIRT2 in free form
(A) Overall structures of SIRT2 in the free form. SIRT2 is colored as in Figure 7.
 
(B) Molecular surfaces of SIRT2 in the free form.
B Small domain
Large domain
Small domain
Large domain
Met299
Phe296
90º
SIRT2-specific
insertion
A Small domain
Large domain
Zn2+
SIRT2-specific
insertion
Cofactor-
binding loop
356
57
26
Figure 9 Superimposition of the four SIRT-S2iL5 molecules
(A) Superimposition of the four SIRT2–S2iL5 complexes in the asymmetric unit
(stereo view). The bound zinc ions are shown as spheres. Mol A–Mol D are colored
gray, green, blue and red, respectively.
(B) Superimposition of S2iL5 in Mol A–Mol D (stereo view).
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Figure 10 Chemical structure of S2iL5
Chemical structure of S2iL5. The peptide is cyclized via a thioether bond between
Y1 and C14. 
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Figure 11 Restults of the Surface plasmon resonance analysis
(A) Binding of S2iL5 to SIRT3 and the alanine mutants of SIRT2 
(B) Binding of the alanine mutants of S2iL5 to SIRT2.
In (A) and (B), the KD values were determined by SPR experiments and are shown
 as means ± s.d. (n = 3).
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Figure 12 Raw data of the Surface plasmon resonance analysis
(A, B) SPR sensorgrams of interactions between SIRT2 (A) and the S2iL5 (B) mutants. The sensorgrams
were obtained using the single-cycle kinetics method, by adding peptides to a SIRT2-immobilized sensor
chip. The raw data (black) were superimposed to theoretical fitting curves based on a 1:1 binding model
(red). Concentrations of added peptide are shown above the sensorgrams. 
In (A) and (B),  residual plots of the fitting curves are shown at the bottom of sensorgrams.
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Figure 13 mFO-DFC omit electron density map of S2iL5
Structure of S2iL5 (stereo view). The mFO – DFC omit electron density map for S2iL5 is 
shown as a gray mesh (contoured at 4σ). S2iL5 is colored as in Figure 7. A water molecule
is shown as a red sphere and hydrogen bonds are shown as green dashed lines.
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Figure 14 S2iL5 recognition by SIRT2
S2iL5 recognition by SIRT2 (stereo view). Hydrogen bonds are shown as green dashed lines.
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Figure 15 Structural comparison of the SIRT2–S2iL5 and SIRT3–AceCS-KAc complexes.
(A) Structure of SIRT2 in complex with S2iL5. The SIRT2-specific insertion (residues 289–304) is 
colored magenta.
(B) Structure of SIRT3 in complex with AceCS-KAc (PDB ID 3GLR) (Jin et al., 2009). 
The bound peptides are colored yellow, and the hydrogen bonds are shown as dashed green lines in 
(A) and (B).
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Figure 16 Sequence alignment of human SIRT1–SIRT3
The conserved residues are shown in red boxes. The secondary structure of SIRT2 is shown
above the sequences. The cofactor-binding loop (residues 92–104) and the SIRT2-specific insertion 
(residues 289–304) are shown in green and magenta boxes, respectively. The figure was prepared 
using TCoffee (Notredame et al., 2000) and ESPript (Gouet et al., 1999).
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Structural change upon S2iL5 binding 
 A comparison between the SIRT2 structures in complex with S2iL5 and in the 
free form 26 revealed the conformational changes that occur in SIRT2 upon S2iL5 
binding (Figure 17). First, the small domain moves toward the large domain upon S2iL5 
binding, as observed in other sirtuins 27-32 (Figure 17). This open-to-closed domain 
movement allows Phe235 to form the catalytic tunnel, and enables Gly236, Glu237 and 
Gln267 to form the  sheet-like interactions with S2iL5 (Figure 4B). Second, the 
SIRT2-specific insertion (residues 289–304) adopts a loop conformation to interact with 
S2iL5 in the S2iL5 complex, whereas it forms an -helix in the free form 26 (Figure 18). 
The side chain of Asp294 hydrogen bonds with the amide groups of Phe296 and Gly302, 
to stabilize the loop conformation. Third, S2iL5 binding induces a local conformational 
change, including the rotation of the side chains of Phe243 and Phe244, which are 
involved in the interactions with S2iL5 (Figure 18). 
 The crystal structure of SIRT2 in complex with ADP-ribose (ADPr), a product 
analog, was reported recently 32. A comparison between the SIRT2 structures in 
complex with S2iL5 and ADPr revealed that ADPr binding induces a local structural 
change in a so-called cofactor-binding loop (residues 92–104) (Figures 19 and 20A). 
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Residues 99–103 in the cofactor-binding loop are disordered in the S2iL5 complex, 
whereas they are ordered and involved in the recognition of ADPr in the ADPr complex. 
Phe96, Arg97 and Tyr104 interact with the nicotinamidic-ribose of ADPr, and Arg97 
interacts with the phosphate group of ADPr. In addition, Lys287 in the large domain 
interacts with the adenine ring of ADPr. In SIRT3, the cofactor-binding loop adopts a 
closed conformation and Arg158 interacts with ADPr in the ADPr complex, whereas it 
adopts an open conformation in the free form and the AceCS-KAc complex (Jin et al., 
2009) (Figure 20B). In contrast, in the SIRT2–S2iL5 complex, the cofactor-binding loop 
adopts a partially-closed conformation without cofactor binding, because Arg97 forms a 
salt bridge network with Glu116 in the small domain and R9 of S2iL5 (Figures 19 and 
20A). Unlike the SIRT2–S2iL5 complex, Arg158 cannot form a salt bridge network 
with Glu177 and AceCS-KAc in the SIRT3–AceCS-KAc complex, since R9 of S2iL5 
corresponds to M644 of AceCS-KAc. 
 The two domains in the ADPr complex adopt a closed conformation, as 
observed in the S2iL5 complex 32 (Figure 17). However, in the ADPr complex, the 
SIRT2-specific insertion mimics a substrate peptide and interacts with the active-site 
groove of a neighboring SIRT2 molecule in the crystallographic asymmetric unit. This 
observation suggested that the closed conformation observed in the ADPr complex is 
36
not due to ADPr binding, but rather to crystal packing interactions. This is consistent 
with the notion that the peptide substrate, but not the cofactor NAD+, induces an 
open-to-closed domain movement (Cosgrove et al., 2006). This mechanism was also 
reported for other sirtuins. The crystal structure of SIRT3, along with isothermal 
titration calorimetry experiments, indicated that the binding of the peptide substrate to 
SIRT3 supports the binding of NAD+ 29. In addition, the crystal structures of a bacterial 
sirtuin revealed that the binding of the peptide substrate induces an open-to-closed 
domain movement 33. 
 A comparison between the SIRT2 structures in the free form 26 and in the 
complex with S2iL5 and ADPr 32 revealed that the SIRT2-specific insertion can adopt 
different conformations (Figure 17). A comparison between the S2iL5 and ADPr 
complexes indicated that the insertion loop in the ADPr complex interferes with the  
sheet-like interaction between S2iL5 and SIRT2 in the S2iL5 complex (Figure 19), 
suggesting that the insertion loop in the ADPr complex is displaced for the substrate 
peptide binding. Given that this flexible SIRT2-specific insertion is involved in the 
interaction with S2iL5 (in the S2iL5 complex) and a neighboring SIRT2 molecule (in 
the free form and ADPr complex), it may play a role in the recognition of the substrate 
37
peptides, although further studies will be required to elucidate its physiological 
function. 
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Figure 17 Structural change in SIRT2
Comparison between SIRT2 structures in the free form (PDB ID 1J8F; gray), and in complex with
S2iL5 and ADPr (PDB ID 3ZGV; beige) (stereo view). The structures are superimposed based on
their large domains. S2iL5 and ADPr are shown as stick models. The bound zinc ions are shown
as spheres.
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Figure 18 Close up of the structural change between SIRT2-S2iL5 complex
and free form
Structural comparison of the S2iL5 complex with the free form (PDB ID 1J8F; gray)
(stereo view).
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Figure 19 Close up of the structural change between SIRT2 in complex with S2iL5
and ADPr
Structural comparison of the S2iL5 complex with the ADPr complex (PDB ID 3ZGV; beige)
 (stereo view). The disordered region (residues 99-103) in the S2iL5 complex is indicated by
green dots. SIRT2 and S2iL5 complex is colored as in Figure 7.
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Figure 20 Structural comparison of the cofactor-binding loops in SIRT2 and SIRT3
(A) Superimposition of SIRT2 in the free form (PDB ID 1J8F; gray) and in the complex with
S2iL5 (the same color code as in Figure 7) and ADPr (PDB ID 3ZGV; beige) (stereo view).
The disordered region (residues 99–103) in the S2iL5 complex is indicated by green dots.
(B) Superimposition of SIRT3 in the free form (PDB ID 3GLS; gray) and in the complex with 
AceCS-KAc (PDB ID 3GLR; the same color code as in Figure 17B) and ADPr (PDB ID 4BN4;
 beige) (stereo view).
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Mutational analysis 
 To confirm the functional significance of the observed interactions between 
SIRT2 and S2iL5, I determined the KD values between S2iL5 and alanine mutants of 
SIRT2, by surface plasmon resonance (SPR) (Figures 11A and 12A). The F244A mutant 
showed the most pronounced reduction in the affinity for S2iL5 (KD = 4.0 nM), 
confirming the importance of the interactions between Phe244 and S2iL5. The E116A 
and E120A mutants showed reduced affinity for S2iL5 (KD = 1.7 and 2.2 nM, 
respectively), establishing the importance of the salt bridges between R9 of S2iL5 and 
Glu116 and Glu120 of SIRT2. The Q265A and S271A mutants showed reduced affinity 
for S2iL5 (KD = 1.8 and 1.8 nM, respectively), confirming the importance of the 
hydrogen-bonding interactions between T10 and Gln265 and between Y4 and Ser271. 
The D294A mutant showed reduced affinity (KD = 1.4 nM), suggesting the functional 
significance of the helix-to-coil transition in the SIRT2-specific insertion for S2iL5 
binding. In contrast, the F296A, M299A and M301A mutants showed almost no 
reduction in their affinities for S2iL5, possibly because S2iL5 binds to SIRT2 through 
multiple interactions. I also determined the KD values between SIRT2 and alanine 
mutants of S2iL5 (Figures 11B and 12B). Among the S2iL5 mutants tested, the R9A 
mutant showed the most pronounced reduction in the affinity for SIRT2 (KD = 7.9 nM), 
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confirming the importance of the salt bridges between R9 of S2iL5 and Glu116 and 
Glu120 of SIRT2. This result is consistent with the increased KD for the E116A and 
E120A mutants of SIRT2. The R8A mutant exhibited reduced affinity (KD = 3.8 nM), 
verifying the functional significance of the PBI-like conformation of S2iL5, which is 
maintained by the R8-mediated intramolecular hydrogen-bonding network. The Y4A 
and H5A mutants showed reduced affinities (KD = 1.9 and 2.4 nM, respectively). The 
Y4A/R9A/Y12A triple mutant showed an additive decrease in the affinity (KD = 29 nM), 
as compared with the single mutants (Y4A, R9A and Y12A) and the double mutants 
(Y4A/R9A, R9A/Y12A and Y4A/Y12A). Notably, the Y4A/R9A/Y12A mutant showed 
markedly reduced affinity (KD = 29 nM), as compared with the Y4A/R9A mutant (KD = 
5.8 nM), although the Y12A mutant showed no reduction in the affinity (KD = 0.42 nM). 
These results indicated that the multiple interactions synergistically contribute to the 
binding of S2iL5 to SIRT2. I further determined the KD values between SIRT2 and a 
14-aa linear peptide, in which the amino group of Y1 in S2iL5 is acetylated, and a 5-aa 
short linear peptide corresponding to H5–R9 of S2iL5. The 14-aa linear peptide showed 
a marked decrease in the affinity (KD = 6.8 nM), whereas the 5-aa linear peptide showed 
a drastic reduction in the affinity (KD = 145 nM). Altogether, the mutational analyses 
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confirmed the functional significance of the observed binding mode between SIRT2 and 
S2iL5, and indicated the synergistic contributions of the multiple interactions. 
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Structural plasticity of macrocyclic peptide inhibitors 
 Using the RaPID system 20,21, I previously developed macrocyclic peptide 
inhibitors against a variety of enzymes, such as SIRT2 deacetylase 19, E6AP ubiquitin 
ligase 20, and Akt2 kinase 34. These studies demonstrated the potential of the RaPID 
system for the discovery of macrocyclic peptide inhibitors with high selectivity and 
potency. However, their inhibitory mechanisms have remained unclear, since no crystal 
structure of an enzyme–macrocyclic peptide complex has been solved. Recently, the 
crystal structures of a MATE multidrug transporter in complex with in vitro selected 
macrocyclic peptides, MaD5 and MaL6, which selectively inhibit the drug extrusion 
activity of the MATE transporter has been reported 35. The structures revealed that 
MaD5 and MaL6 adopt lariat- and -hairpin-like structures, respectively, to bind the 
central cleft of the transporter. Thus, the crystal structures of SIRT2 and MATE in 
complex with the macrocyclic peptides highlighted the structural plasticity of the 
macrocyclic peptides, which confers extremely high affinities to various target proteins.
  
 Notably, the present structure of SIRT2 in complex with S2iL5 further revealed 
that S2iL5 binding induces an unanticipated conformational change in the flexible 
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SIRT2-specific region. The functional data demonstrated the potential role of this 
dynamic structural change for S2iL5 binding. It seems unlikely that small molecule 
inhibitors could induce such large structural changes in their target proteins, due to the 
limited number of inhibitor–protein interactions. Thus, the ability to bind to a target 
protein, by inducing a structural change within the target, is likely to be a unique 
advantage for macrocyclic peptide inhibitors36. 
 I believe that the present structural information will be helpful for inventing 
drugs to improve ischemic conditions in the near future. 
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